Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
General22 hours agoOf saints and sinners | The Spectator Australia
-
General22 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News12 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General22 hours agoWhy the nation needs the Nationals to ditch Net Zero